Is DCGI drug approval the same as trademark registration?

No. The Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India (DCGI), regulates the manufacturing, sale, and safety approval of drugs under the Drugs and Cosmetics Act, 1940. This determines whether a drug can be legally manufactured and sold. Trademark registration under the Trade Marks Act, 1999, administered separately by the Trademark Registry, protects the brand name and logo from being copied by competitors. A Vasai pharma manufacturer needs both: DCGI/state drug licensing approval to legally manufacture, and trademark registration to protect the brand name from imitation by other companies.

Can a generic drug name be trademarked in India?

No. The International Nonproprietary Name (INN) of a drug — the generic scientific or chemical name assigned by the World Health Organization, such as Paracetamol or Metformin — cannot be trademarked by any single company, as it must remain available for all manufacturers to use. However, a distinctive brand name created around or derived from the generic name (such as a third-party manufacturer's specific product name) can be trademarked, provided it is sufficiently distinctive and not deceptively similar to existing registered marks in Class 5.

What trademark class should a Vasai pharmaceutical manufacturer use?

Pharmaceutical companies in Vasai primarily need Class 5, which covers pharmaceuticals, medicinal preparations, dietary supplements, and veterinary preparations. Companies that also manufacture or supply pharmaceutical equipment and machinery — common among Vasai's industrial base — may need Class 7 or Class 9 for machinery and instruments. Companies engaged in retail distribution of pharmaceutical products additionally need Class 35. Third-party manufacturers and PCD pharma franchise companies should register both their company brand name and individual product brand names under Class 5.

What happened in the Novo Nordisk vs Dr Reddy's Olymviq case and why does it matter for Vasai pharma companies?

In a 2026 trademark dispute, Novo Nordisk sued Dr Reddy's Laboratories in the Delhi High Court, alleging that the drug name 'Olymviq' was deceptively similar to its diabetes drug Ozempic. This case highlights India's strict approach to pharmaceutical trademark similarity even between branded products from major pharmaceutical companies. For Vasai's pharma manufacturers — many operating as third-party and contract manufacturers serving multiple brand owners — this underscores the importance of a thorough trademark search and clearance before finalising any product brand name, since even established companies face significant litigation risk over name similarity.

How does third-party pharmaceutical manufacturing in Vasai affect trademark strategy?

Vasai is home to numerous third-party and contract pharmaceutical manufacturers who produce medicines, nutraceuticals, herbal products and cosmetics on behalf of other brand owners. In this business model, trademark ownership requires careful contractual clarity: typically, the brand owner (the company whose name appears on the product) holds the trademark registration, while the Vasai-based manufacturing company may separately trademark its own corporate name and any proprietary processes or formulations it markets independently. Manufacturing agreements should explicitly address which party owns trademark rights to products developed or co-branded during the manufacturing relationship.

Trademark Registration By TNP

Q: Why is pharmaceutical trademark registration treated differently from other industries in India?

Pharmaceutical trademarks fall under Class 5 of the Nice Classification and are subject to significantly stricter scrutiny than trademarks in most other classes. This is because confusion between drug names is not merely a commercial issue — it is a public health and patient safety issue. Courts have repeatedly held that even the slightest probability of confusion in medicinal trademarks is sufficient grounds to restrain a similar brand name, since a pharmacist or patient confusing two similarly named drugs with different therapeutic effects could cause serious harm. The Supreme Court's landmark Cadila Healthcare case (2001) established that pharmaceutical trademarks require a higher standard of distinctiveness than ordinary consumer goods.

Q: What is deceptive similarity in pharmaceutical trademarks under Indian law?

Deceptive similarity under Section 11 and Section 9 of the Trade Marks Act, 1999 refers to a mark so similar to an existing mark — in sound, appearance, or meaning — that it is likely to cause confusion among consumers. In the pharmaceutical context, courts assess phonetic similarity, visual resemblance, the nature and therapeutic use of the drug, and the likelihood of confusion among doctors, pharmacists or patients. The landmark Cadila Healthcare Ltd v Cadila Pharmaceuticals Ltd (2001) Supreme Court case established these factors as the test for deceptive similarity in drug names, given the serious public health risk of medication errors.

Vasai — India's Growing Pharmaceutical Manufacturing Hub

The Vasai-Virar region in Maharashtra has rapidly grown into a recognised hub for pharmaceutical manufacturing in India. With proximity to Mumbai, modern industrial infrastructure, and compliance-driven operations, Vasai is now home to a diverse ecosystem of pharmaceutical companies — from established multinational manufacturers to specialised third-party and contract manufacturing operations.

The region's pharmaceutical ecosystem includes companies engaged in formulation manufacturing, sterile injectables, nutraceuticals, herbal products, cosmetics, and pharmaceutical machinery and equipment supply — reflecting both the manufacturing base itself and the supporting industrial ecosystem around it.

Formulation Manufacturers

Sterile Injectables

Third-Party Manufacturing

Nutraceuticals

Herbal & Ayurvedic Products

Pharma Machinery Suppliers

PCD Pharma Franchise

Anti-Infective Therapeutics

📰 Source — Pharma Industry Coverage, 2025

"The Vasai-Virar region in Maharashtra has rapidly grown into a leading hub for pharmaceutical manufacturing. From multinational giants to specialized third-party manufacturers, the pharmaceutical ecosystem here is diverse and dynamic. Whether you are a healthcare brand, distributor, or investor, Vasai offers countless opportunities."

Vasai is also a significant base for pharmaceutical machinery and equipment manufacturing — suppliers of processing equipment, packaging machines, granulators, blenders, and dryers serving pharma companies across the Mumbai Metropolitan Region and beyond. This creates a distinct second category of trademark need within Vasai's pharma ecosystem: equipment and machinery brands, separate from drug product brands.

Why Pharmaceutical Trademarks Face the Strictest Scrutiny in Indian Law

Unlike a clothing brand or a food product, a confused trademark in the pharmaceutical sector is not merely a commercial inconvenience — it is a direct patient safety risk. If a pharmacist or patient mistakes one drug for another due to a similar-sounding or similar-looking brand name, the consequence can be a serious medication error, particularly when the two drugs have different therapeutic effects, dosages, or are intended for entirely different conditions.

Indian courts have recognised this distinction explicitly. The threshold for finding "deceptive similarity" between two trademarks — already a serious matter under Section 11 of the Trade Marks Act, 1999 — is applied even more strictly in Class 5 than in other trademark classes.

"Even the slightest probability of confusion in medicinal trademarks is sufficient to restrain the use of a similar brand name." — Bombay High Court, 2023

test.

Landmark Drug Trademark Cases Every Vasai Pharma Company Should Know

Cadila Healthcare Ltd v Cadila Pharmaceuticals Ltd

Supreme Court of India · 2001

Established the foundational test for deceptive similarity in pharmaceutical trademarks in India. The Court held that drug names require a stricter standard of distinctiveness than ordinary consumer goods, given the public health risk of confusion. Factors assessed include phonetic similarity, visual resemblance, the nature and therapeutic use of the drug, and likelihood of confusion among doctors, pharmacists or patients.

📌 Impact: This remains the controlling precedent cited in virtually every pharmaceutical trademark dispute in India today, including by the Trademark Registry during Class 5 examination.

Novo Nordisk v Dr Reddy's Laboratories — "Olymviq" vs Ozempic

Delhi High Court · 2026

Novo Nordisk sued Dr Reddy's, alleging the drug name "Olymviq" was deceptively similar to its globally recognised diabetes drug Ozempic. This case highlights that even major, well-resourced pharmaceutical companies face significant litigation risk over name similarity, and that India's strict approach to pharmaceutical trademark similarity applies regardless of company size.

📌 Impact: Reinforces that thorough trademark clearance searches are essential before finalising any drug brand name — even names that seem clearly distinct on the surface can attract a serious infringement claim.

Letroz v Letero

Delhi High Court · 2022

The Court allowed both drug names to coexist, because both were derived from the same INN (International Nonproprietary Name) "Letrozole" and were prescribed specifically by specialised oncologists — a narrow, expert prescriber base that significantly reduced the realistic risk of confusion among the relevant audience.

📌 Impact: Demonstrates that the prescriber/patient context matters — specialist drugs with a narrow, expert prescribing audience may face a different similarity analysis than over-the-counter medications used by the general public.

Crocin v Crosin

Referenced widely in Class 5 trademark literature

A frequently cited example of the kind of phonetic and visual similarity dispute common in the pharmaceutical sector — illustrating how closely related brand names can create genuine confusion risk even when neither name is identical to the other.

📌 Impact: A practical illustration of why Class 5 trademark examiners scrutinise even minor similarities far more closely than in other product categories.

🏛️ Legal basis: Section 9 and Section 11, Trade Marks Act, 1999 (grounds for refusal and deceptive similarity). Sections 28 and 29 (infringement). Case law: Cadila Healthcare Ltd v Cadila Pharmaceuticals Ltd, A.I.R. 2001 S.C. (Supreme Court). Source for recent cases: ICLG India 2026, StudyIQ Legal Analysis (March 2026), SSRana & Co.

DCGI Drug Approval vs Trademark Registration — The Critical Difference

One of the most common points of confusion among Vasai pharma manufacturers is assuming that drug licensing approval automatically protects the brand name. It does not. These are two entirely separate regulatory and legal frameworks.

Drug Safety & Manufacturing Law

DCGI / CDSCO Approval

Governed by the Drugs and Cosmetics Act, 1940, regulated by the Central Drugs Standard Control Organisation (CDSCO) headed by the Drugs Controller General of India.

Mandatory for legally manufacturing and selling any drug
Covers safety, efficacy, manufacturing standards, quality control
State drug licensing required for the Vasai manufacturing facility itself
Does NOT protect the brand name from being copied by a competitor
A drug license number does not confer trademark ownership

Intellectual Property Law

Trademark Registration

Governed by the Trade Marks Act, 1999, administered by the CGPDTM (Trademark Registry) — entirely separate from CDSCO.

Optional but essential for protecting the brand name and logo
Filed under Class 5 for pharmaceutical preparations
Gives exclusive nationwide rights to use the brand name
Allows legal action against a competitor using a similar drug name
Required separately from any drug manufacturing license

💡 A Vasai Pharma Manufacturer Needs Both

DCGI/state drug license approval allows your facility to legally manufacture a product. Trademark registration protects the brand name on that product from competitor imitation. Securing one does not secure the other — and many Vasai manufacturers focus heavily on drug licensing compliance while overlooking trademark protection, leaving the brand name itself vulnerable. Trademark Registration by TNP handles the trademark side specifically — call 77589 38424.

Can You Trademark a Generic Drug Name? INN Rules Explained

The International Nonproprietary Name (INN) — the generic, scientific or chemical name assigned to a drug by the World Health Organization (such as Paracetamol, Metformin, or Letrozole) — cannot be trademarked by any single company. INN names are deliberately kept open for use by all manufacturers, since they identify the actual pharmacological substance rather than any particular company's product.

What can be trademarked is a distinctive brand name created around or derived from the generic substance — provided the brand name itself is sufficiently distinctive and not deceptively similar to existing registered marks in Class 5. This is precisely the naming challenge facing Vasai's third-party manufacturers: hundreds of companies may legally manufacture the same generic molecule, but each needs a genuinely distinct brand name to market it under.

Naming Element	Trademark Status	Example
INN / Generic Name	Not Registrable	Paracetamol, Metformin, Amoxicillin
Distinctive Brand Name	Registrable	A company's own coined product name
Brand Name Derived from INN (suggestive)	Registrable with care	Names that hint at the molecule but aren't the INN itself
Company / Manufacturer Name	Registrable	The pharmaceutical company's own corporate brand

⚠️ The Coining Challenge for Vasai's Third-Party Manufacturers

Class 5 is one of the most crowded classes in the Indian trademark registry, given the sheer volume of pharmaceutical brand names already registered. Vasai's third-party manufacturers — who frequently coin new product brand names for different brand-owner clients — face a particularly acute version of this challenge, needing a fresh, clearable, distinctive name for each new product launch.

Trademark Classes for Vasai Pharmaceutical Businesses

Class	Covers	Relevant to Vasai Pharma Sector	Priority
Class 5	Pharmaceutical and medicinal preparations, dietary supplements, veterinary preparations	The primary class for any drug, formulation, or nutraceutical manufacturer	Essential
Class 3	Cosmetics and non-medicated toiletries	Cosmetic and personal care product manufacturers (common alongside pharma in Vasai)	Situational
Class 1	Chemical raw materials used in drug or supplement formulation	Suppliers of chemical ingredients distinct from the finished drug product	Situational
Class 7	Machines and machine tools	Vasai's pharmaceutical machinery manufacturers (granulators, blenders, mixers)	Medium — Vasai's equipment sector
Class 9	Scientific instruments, measuring apparatus	Pharmaceutical processing and packaging equipment suppliers	Medium — Vasai's equipment sector
Class 35	Retail, wholesale trade, distribution	PCD pharma franchise companies and distributors	Medium
Class 42	Scientific and technological services, R&D	Pharma companies offering formulation R&D or testing services	Situational

🏛️ Important distinction: Chemical ingredients or raw materials used in drug formulation fall under Class 1, not Class 5 — a common point of confusion. Class 5 covers the finished pharmaceutical or medicinal preparation itself. Trademark Registration by TNP identifies the correct class structure for your specific Vasai pharma business. Call 77589 38424.

Trademark Strategy for Third-Party & Contract Manufacturers

Vasai's pharma ecosystem includes a significant number of third-party and contract manufacturers — companies that manufacture pharmaceuticals, nutraceuticals, herbal products and cosmetics on behalf of other brand owners under PCD (Propaganda Cum Distribution) franchise or contract manufacturing arrangements. This business model raises distinct trademark ownership questions that standard manufacturing businesses don't face.

Who Owns the Trademark in a Manufacturing Relationship?

Typically, the brand owner — the company whose name and logo appear on the finished product packaging — holds the trademark registration for that product. The Vasai-based manufacturing company generally does not own trademark rights to products it manufactures purely on a contract basis for another company's brand, unless the manufacturing agreement specifies otherwise.

What Should the Vasai Manufacturer Trademark Separately?

The manufacturing company's own corporate name and logo should be registered as a trademark regardless of the contract manufacturing arrangements — this protects the manufacturer's own reputation in the market, independent of any specific brand-owner relationship. If the manufacturer also markets its own proprietary product lines directly (common among PCD pharma franchise companies), those product brand names need separate Class 5 trademark registration.

💡 Manufacturing Agreement Clarity Matters

Manufacturing and franchise agreements between Vasai-based third-party manufacturers and their brand-owner clients should explicitly address which party owns trademark rights to any product developed or co-branded during the relationship — particularly for products where the manufacturer contributed to formulation development. Ambiguity here can create costly disputes if the relationship later changes. Trademark Registration by TNP advises Vasai pharma manufacturers on this contractual and trademark intersection. Call 77589 38424.

Step-by-Step: Registering a Defensible Drug Brand Name

Comprehensive Class 5 Availability Search

Given how crowded Class 5 is and how strictly similarity is judged, a basic name search is insufficient. The search must specifically check for phonetic similarity, visual resemblance, and conceptual similarity to existing registered Class 5 marks — not just exact name matches. This is the single most important step in pharma trademark strategy, given the heightened deceptive similarity standard established by Cadila Healthcare.

⏱ 2–3 days for thorough Class 5 search

Assess Distinctiveness and INN Distance

Confirm the proposed brand name is sufficiently distinct from the drug's generic INN name and from existing branded competitors treating similar conditions. Names that closely echo the INN, or that are commonly used across the therapeutic category, face a higher risk of both Section 9 (descriptiveness) and Section 11 (similarity) objections.

⏱ Part of initial consultation

Identify Correct Classes

Class 5 for the drug product itself; additional classes (1, 7, 9, 35) as relevant for raw materials, machinery, or distribution activities. Third-party manufacturers should also confirm whether the company name itself needs separate registration alongside individual product names.

⏱ Same consultation

File Form TM-A on ipindiaonline.gov.in

Application filed electronically with the government fee paid per class. Application number issued immediately — the ™ symbol may be used on packaging, marketing materials, and product literature from this date.

⏱ Same day — filing date secured

Heightened Examination — Expect Closer Scrutiny

Class 5 applications typically receive more rigorous examination than other classes, given the established legal standard for deceptive similarity in pharmaceutical marks. If an Examination Report is issued under Section 11, a well-supported counter-statement addressing the Cadila Healthcare factors (phonetic, visual, conceptual similarity; nature of goods; likely confusion among the relevant prescriber/patient audience) is essential within the 30-day deadline.

⚠️ Higher objection likelihood in Class 5

Publication, Opposition Risk & Registration

After examination clearance, the mark is published for a 4-month opposition window. Given the competitive density of Class 5, established pharma companies actively monitor the Trademark Journal for similar marks and frequently file oppositions. If uncontested, the registration certificate is issued — typically 18–24 months total, sometimes longer for Class 5 given the additional scrutiny.

⏱ 18–24+ months total

Government Fees for Trademark Registration — Official 2026 Schedule

Applicant Type	e-Filing Fee (per class)	Who Qualifies
Individual / Sole Proprietor	₹4,500	Individual applicants
MSME — Udyam Registered	₹4,500	Most smaller Vasai pharma manufacturers and PCD franchise operators
DPIIT-Recognised Startup	₹4,500	Valid DPIIT recognition at time of filing
Company / LLP	₹9,000	Larger pharmaceutical manufacturing companies and corporates

Under the Trade Marks Rules, 2017, many of Vasai's smaller third-party manufacturers and PCD pharma franchise operators qualify as MSMEs under Udyam registration, accessing the reduced ₹4,500 per class rate. Larger formulation manufacturers structured as private limited companies typically pay ₹9,000 per class. Given Class 5's crowded landscape, budgeting for potential objection reply and hearing costs alongside the base filing fee is prudent.

Trademark Registration for Pharmaceutical Companies in Vasai — The Complete 2026 Guide